Combination of vaccination and inhibition of MHC class I restricted antigen presentation

Patent metadata

Field	Value
Publication number	US-9737595-B2
Application number	US-201113824502-A
Country	US
Kind code	B2
Filing date	Dec 27, 2011
Priority date	Dec 29, 2010
Publication date	Aug 22, 2017
Grant date	Aug 22, 2017

Abstract

The present invention relates to a vaccine/inhibitor combination comprising as a vaccine at least one antigen and as an inhibitor at least one inhibitor of the major histocompatibility complex (MHC) class I restricted antigen presentation. The present invention furthermore relates to a method of vaccination of a mammal using the inventive vaccine/inhibitor combination. The present invention also provides kit of parts comprising the inventive vaccine/inhibitor combination, preferably in different parts of the kit, e.g. for prior, concurrent or subsequent administration of the different parts. Additionally the invention relates to a pharmaceutical composition comprising the inventive vaccine/inhibitor combination to further improve the immune response against tumor cells and infected cells having lost the capability of MHC class I restricted antigen presentation.

First claim

The invention claimed is:

1. A method for stimulating an anti-tumor immune response in a subject having a cancer, comprising administering to a subject in need thereof an effective amount of:
(a) a mRNA encoding an tumor cell antigen that is expressed in the cancer, wherein the antigen does not comprise an MHC class I heavy chain or β2m fusion protein; and
(b) a mRNA encoding a TAP inhibitor.

2. The method of claim 1 , wherein the mRNA encoding the antigen and the mRNA encoding the TAP inhibitor are administered at the same time.

3. The method of claim 1 , wherein the mRNA encoding the TAP inhibitor and the mRNA encoding the antigen are administered at different times.

4. The method of claim 1 , wherein the mRNA encoding the TAP inhibitor and the mRNA encoding the antigen are administered to the subject at different administration sites.

5. The method of claim 1 , wherein the method does not further comprise administering an antigen presenting cell.

6. The method of claim 1 , wherein the mRNA encoding the TAP inhibitor encodes the UL49.5 polypeptide.

7. The method of claim 1 , wherein the mRNA encoding the antigen is administered before the mRNA encoding the TAP inhibitor.

8. The method of claim 1 , wherein at least a portion of the mRNA encoding the antigen is complexed with protamine.

9. The method of claim 1 , wherein the mRNA encoding the antigen or the mRNA encoding the TAP inhibitor is administered intradermally.

10. The method of claim 9 , wherein the mRNA encoding the antigen and the mRNA encoding the TAP inhibitor are administered intradermally.

11. A method for stimulating an anti-tumor immune response in a subject having a cancer, comprising administering to a subject in need thereof an effective amount of:
(a) a mRNA encoding a cancer or tumor cell antigen that is expressed in the cancer, wherein the antigen does not comprise an MHC class I heavy chain or β2m fusion protein; and
(b) a mRNA encoding a TAP inhibitor comprising the UL49.5 polypeptide.

12. The method of claim 11 , wherein the mRNA encoding a cancer or tumor cell antigen or the mRNA encoding a TAP inhibitor is administered intradermally.

13. The method of claim 12 , wherein the mRNA encoding a cancer or tumor cell antigen and the mRNA encoding a TAP inhibitor are administered intradermally.

14. The method of claim 11 , wherein the mRNA encoding the cancer or tumor cell antigen is administered before the mRNA encoding the TAP inhibitor.

15. The method of claim 11 , wherein at least a portion of the mRNA encoding the cancer or tumor cell antigen is complexed with protamine.

16. The method of claim 11 , wherein the mRNA encoding the TAP inhibitor and the mRNA encoding the cancer or tumor cell antigen are administered to the subject at different administration sites.

Assignees

• Lorenz Christina
• Fotin-Mleczek Mariola
• Kallen Karl-Josef
• Curevac Ag

Inventors

• Lorenz Christina
• Fotin-Mleczek Mariola
• Kallen Karl-Josef

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K2039/55516

  Proteins; Peptides · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• A61K2039/53

  DNA (RNA) vaccination · CPC title

• A61P31/12

  Antivirals · CPC title